Form 4: KalVista CDO Exercises Stock Options
Insider Transaction Report
KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, exercised 87,390 employee stock options, acquiring common stock.
Summary
- Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, Inc. (KALV), reported a transaction on November 20, 2025.
- Yea exercised 87,390 employee stock options at an exercise price of $0.0043 per share.
- The options were 100% vested and had an expiration date of March 30, 2026.
- Following the exercise, Yea acquired 87,390 shares of common stock.
- After this transaction, Christopher Yea beneficially owns 220,964 shares of KalVista Pharmaceuticals, Inc. common stock directly.
- No derivative securities are beneficially owned by Yea following this transaction, as the options were exercised.
Sentiment
Score: 6
Explanation: The exercise of employee stock options by a Chief Development Officer is a routine compensation event. It can be viewed as slightly positive as it indicates the officer is taking ownership of shares, potentially signaling confidence in the company's future, though the exercise price is very low, suggesting these were likely granted long ago.
Positives
- The Chief Development Officer, Christopher Yea, increased his direct ownership in the company by exercising stock options, which can signal confidence in the company's future prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance.
Industry Context
Insider transactions, such as the exercise of stock options, are a routine part of executive compensation in publicly traded biotechnology and pharmaceutical companies. While not indicative of immediate strategic shifts, an officer increasing their direct shareholding can be interpreted as a sign of continued commitment and belief in the company's long-term value.
Stakeholder Impact
- Shareholders may view the increased direct ownership by a key executive as a positive signal of management's alignment with shareholder interests and confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 11/20/2025 | Date of transaction where employee stock options were exercised and common stock was acquired. |
| 11/21/2025 | Date the Form 4 was signed by Benjamin L. Palleiko, Attorney-in-Fact. |
| 03/30/2026 | Expiration date of the employee stock option that was exercised. |
Keywords
KalVista Pharmaceuticals, KALV, Christopher Yea, Chief Development Officer, Stock Options, Insider Transaction, Form 4, Equity Acquisition, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.